Abstract 1011P
Background
Portal vein tumor thrombus (PVTT) has a high incidence and poor prognosis in hepatocellular carcinoma (HCC) patients, and the treatment demand for such patients is currently unmet. This study aimed to evaluate efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and sintilimab in HCC with PVTT.
Methods
In this prospective study, eligible participants were enrolled and randomized (1:1) into TACE combined with lenvatinib and sintilimab (TACE-LEN-SIN) group and TACE combined with lenvatinib (TACE-LEN) group. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included overall survival (OS), objective response rate (ORR) and disease control rate (DCR) according to mRECIST, and safety.
Results
116 patients were enrolled from January 2022 to December 2022, 58 patients in each group. Patients had a median age of 50 (range, 51-64.2) years and mostly were male (80.2%). Hepatitis B virus infection was the main cause of HCC (85.3%). 37 (31.9%) patients had extrahepatic metastases. As of April 2023, 49 (84.5%) patients in the TACE-LEN group had disease progression and 38 (65.5%) died, while 37 (63.8%) patients in the TACE-LEN-SIN group had disease progression and 16 (27.6%) died. Both median PFS (4.17 vs. 3.33 months, P = 0.01) and median OS (not reached (NR) vs. 8.53 months, P = 0.003) in the TACE-LEN-SIN group were significantly longer than those in the TACE-LEN group. ORR (22.4% vs. 12.1%, P = 0.219) and DCR (69.0% vs. 53.4%, P = 0.127) were slightly higher in the triple group than in the dual group. The results of multivariate Cox regression also found that TACE-LEN-SIN treatment was an independent protective factor for PFS (HR: 0.62, 95% CI: 0.40 – 0.95, P = 0.028) and OS (HR: 0.45, 95% CI: 0.25 – 0.82, P = 0.008). The most common adverse events (AEs) were hypertension, diarrhea and fatigue. And no significant differences in the incidence of AEs between the two groups, except for those related to Sintilimab.
Conclusions
TACE combined with lenvatinib and sintilimab improved survival outcomes without increasing the unpredictable safety profile compared with TACE combined with lenvatinib for HCC with PVTT.
Clinical trial identification
ChiCTR2200066830.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18